immunogenicity


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to immunogenicity: humoral immunity

immunogenicity

 [im″u-no-jĕ-nis´ĭ-te]
the ability of a substance to provoke an immune response or the degree to which it provokes a response. adj., adj immunogen´ic.

an·ti·ge·nic·i·ty

(an'ti-jĕ-nis'i-tē),
The state or property of being antigenic.
Synonym(s): immunogenicity

immunogenicity

/im·mu·no·ge·nic·i·ty/ (-jĕ-nis´it-e) the property enabling a substance to provoke an immune response, or the degree to which a substance possesses this property.immunogen´ic

immunogenicity

immunogenicity

the ability of a substance to provoke an immune response or the degree to which it provokes a response.
References in periodicals archive ?
biotech quality and immunogenicity reviewer at FDA, will explain how to identify and mitigate immunogenicity-related risks for different product types
The PolyTherics group will provide immunogenicity testing, antibody humanisation and protein re-engineering technologies through its Antitope subsidiary, including
Implications of Immunogenicity of Biologic DMARDs on the Treatment of Rheumatoid Arthritis (16)
Implementing the correct immunogenicity assay for successful drug development with an A-Z of everything you need to know with Dan Sikkema, GlaxoSmithKline
The I-MUNE Assay has been acknowledged as a standard not only for determining immunogenicity, but for providing the critical information to re-engineer proteins to make them safer for consumer and health care applications," said Michael Arbige, Ph.
The title of the talk is "Application of SQI Multiplex Platform in Immunogenicity Testing -- Epitope Mapping and Isotyping.
However, in some patients, biopharmaceuticals can trigger an immune reaction, a phenomenon known as immunogenicity.
Richard Koup of the VRC, delivered an oral presentation, "Update on Safety and Immunogenicity of VRC Products," summarizing data from several ongoing studies sponsored by the NIH's HIV Vaccine Trials Network ("HTVN"), the International AIDS Vaccine Initiative ("IAVI") and the U.
Nektar Advanced PEGylation has the potential to improve the safety and efficacy of therapeutic agents by increasing drug circulation time in the bloodstream, decreasing immunogenicity and dosing frequency, increasing bioavailability and improving drug solubility and stability.
Method for Determining Immunogenicity Could Enhance Development of Protein Therapeutics
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus.
Positive Phase 1 Safety and Immunogenicity Results to be Presented at 2011 ASTMH Meeting -